Incyte INCY is set to give its latest quarterly earnings report on Tuesday, 2025-07-29. Here's what investors need to know before the announcement. Analysts estimate that Incyte will report an ...
Incyte primarily derives product revenues from the sales of its lead drug, Jakafi (ruxolitinib), in the United States, as well as from the sales of other marketed drugs. Its momentum is likely to have ...
In the last three months, 7 analysts have published ratings on Incyte (NASDAQ:INCY), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback